These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28964743)

  • 1. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada.
    Chisholm J; von Tigerstrom B; Bedford P; Fradette J; Viswanathan S
    Cytotherapy; 2017 Dec; 19(12):1400-1411. PubMed ID: 28964743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
    Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
    Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products.
    Wang J; Griffiths E; Tounekti O; Nemec M; Deneault E; Lavoie JR; Ridgway A
    Adv Exp Med Biol; 2023; 1430():91-116. PubMed ID: 37526844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulation of cell therapy products in Canada.
    Ridgway AA
    Biologicals; 2015 Sep; 43(5):406-9. PubMed ID: 26141550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon.
    Chisholm J; Ruff C; Viswanathan S
    Cytotherapy; 2019 Jul; 21(7):686-698. PubMed ID: 31196821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada.
    Roy DC; Alarco AM; Isasi R
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():24-8. PubMed ID: 25457957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada.
    Bubela T; Boch R; Viswanathan S
    Front Med (Lausanne); 2019; 6():58. PubMed ID: 30984761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.
    Stacey G; Andrews P; Asante C; Barbaric I; Barry J; Bisset L; Braybrook J; Buckle R; Chandra A; Coffey P; Crouch S; Driver P; Evans A; Gardner J; Ginty P; Goldring C; Hay DC; Healy L; Hows A; Hutchinson C; Jesson H; Kalber T; Kimber S; Leathers R; Moyle S; Murray T; Neale M; Pan D; Park BK; Rebolledo RE; Rees I; Rivolta MN; Ritchie A; Roos EJ; Saeb-Parsy K; Schröder B; Sebastian S; Thomas A; Thomas RJ; Turner M; Vallier L; Vitillo L; Webster A; Williams D
    Regen Med; 2018 Dec; 13(8):935-944. PubMed ID: 30488776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we assure quality without stifling innovation?
    Miller L
    Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):66-7. PubMed ID: 25457966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings: international regulatory considerations on development pathways for cell therapies.
    Feigal EG; Tsokas K; Viswanathan S; Zhang J; Priest C; Pearce J; Mount N
    Stem Cells Transl Med; 2014 Aug; 3(8):879-87. PubMed ID: 25038248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical device regulation for manufacturers.
    McAllister P; Jeswiet J
    Proc Inst Mech Eng H; 2003; 217(6):459-67. PubMed ID: 14702983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell research and therapies in Argentina: the legal and regulatory approach.
    de Arzuaga FC
    Stem Cells Dev; 2013 Dec; 22 Suppl 1():40-3. PubMed ID: 24304074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal and Regulatory Challenges for Emerging Regenerative Medicine Solutions for Diabetes.
    Thom RL; Cronin AJ;
    Transplantation; 2024 May; 108(5):1072-1079. PubMed ID: 37749797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Court of Human Rights' ruling on unproven stem cell therapies: a missed opportunity?
    Rial-Sebbag E; Blasimme A
    Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):39-43. PubMed ID: 25457960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.